ARHGEF2 and neoplasm: Collectively, our findings indicated that GEF-H1 plays a critical role in initiating anti-tumor immunity, particularly upon treatment with MDAs such as ansamitocin-P3, and establishes a framework to guide the development of microtubule-targeting strategies.